Biodistribution and radiation dose estimates for ⁶⁸Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors.

ABSTRACT:

Purpose

Somatostatin receptor antagonists have shown promise for imaging neuroendocrine tumors (NETs) in preclinical studies, but clinical data is still very limited. In this study, we assess the feasibility of using the novel somatostatin antagonist ⁶⁸Ga-DOTA-JR11 for PET imaging of NETs.

Methods

Twenty patients with advanced NETs underwent whole-body PET/CT imaging 60 min after injection of 169 MBq (median) ⁶⁸Ga-DOTA-JR11 as part of a prospective study. Volumes of interest were drawn around up to four ⁶⁸Ga-DOTA-JR11-avid lesions per patient (with uptake greater than liver) and standardized uptake values were estimated. Additionally, target-to-normal tissue ratios were calculated. A subset of six patients had additional imaging (25-min dynam

SUBMITTER: Krebs S 

PROVIDER: S-EPMC6447060 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature